Get the Stockscreener App
51.63
2.70%
-1.43
Exact Sciences Corp stock is traded at $51.63, with a volume of 1.98M.
It is down -2.70% in the last 24 hours and up +13.47% over the past month.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$53.06
Open:
$52.91
24h Volume:
1.98M
Relative Volume:
0.79
Market Cap:
$9.72B
Revenue:
$2.69B
Net Income/Loss:
$-214.04M
P/E Ratio:
-44.13
EPS:
-1.17
Net Cash Flow:
$98.43M
1W Performance:
+0.16%
1M Performance:
+13.47%
6M Performance:
+0.29%
1Y Performance:
-4.65%
1-Day Range:
$51.58
$53.67
1-Week Range:
$50.72
$54.49
52-Week Range:
$39.97
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
51.63 | 9.72B | 2.69B | -214.04M | 98.43M | -1.17 |
|
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
Analysts Have Made A Financial Statement On Exact Sciences Corporation's (NASDAQ:EXAS) First-Quarter Report - Yahoo
Exact Sciences Corporation (NASDAQ:EXAS) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus
Exact Sciences Corp Reports Strong Start to 2025 - TipRanks
Exact Sciences (EXAS) Target Price Raised by Barclays to $75 | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Price Target Raised by RBC Capital | EXAS Stock News - GuruFocus
Exact Sciences: Q1 Earnings Snapshot - GMToday.com
Lobbying Update: $470,000 of EXACT SCIENCES lobbying was just disclosed - Nasdaq
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect - Barchart.com
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday - Benzinga
Exact Sciences (EXAS) Sees Target Price Raised by Baird | EXAS S - GuruFocus
EXAS: Evercore ISI Group Raises Price Target for Exact Sciences - GuruFocus
EXAS: Evercore ISI Group Raises Price Target for Exact Sciences | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Sees Target Price Raised by Baird | EXAS Stock News - GuruFocus
Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance - Benzinga
Exact Sciences (EXAS) Price Target Raised to $72 by Baird Analys - GuruFocus
RBC Raises Price Target on Exact Sciences to $54 From $52, Keeps Sector Perform Rating - marketscreener.com
Exact Sciences (EXAS) Price Target Raised to $72 by Baird Analyst | EXAS Stock News - GuruFocus
S&P 500 Futures Rise in Premarket Trading; McCormick Vtg, Exact Sciences Lead - Barron's
Exact Sciences to Participate in May Investor Conference | EXAS Stock News - GuruFocus
Barclays Elevates Price Target for Exact Sciences (EXAS) to $75 - GuruFocus
Exact Sciences to Participate in May Investor Conference - Business Wire
Barclays Elevates Price Target for Exact Sciences (EXAS) to $75 | EXAS Stock News - GuruFocus
Exact Sciences Corp (EXAS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and New ... - Yahoo Finance
Exact Sciences Corp (EXAS) Q1 2025 Earnings Call Highlights: Str - GuruFocus
Exact Sciences reports Q1 EPS (54c) vs (60c) last year - TipRanks
Exact Sciences Reports Strong Q1 2025 Results - TipRanks
Exact Sciences Q1 2025 slides: revenue growth accelerates, profitability improves By Investing.com - Investing.com South Africa
Exact Sciences (EXAS) Boosts Revenue Outlook; Shares Rise Post-M - GuruFocus
Exact Sciences Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Exact Sciences Corp (EXAS) Q1 2025 Earnings: Revenue Surpasses E - GuruFocus
Exact Sciences Announces First-Quarter 2025 Results | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Surpasses Q1 2025 Expectations with 11% Re - GuruFocus
EXACT Sciences earnings missed by $0.21, revenue topped estimates - Investing.com South Africa
Exact Sciences Q1 2025 slides: revenue growth accelerates, profitability improves - Investing.com
Earnings call transcript: Exact Sciences Q1 2025 sees revenue growth, stock surges - Investing.com
Exact Sciences Q1 Adjusted Loss Narrows, Revenue Rises; Shares Up - marketscreener.com
Exact Sciences stock surges 8% on Q1 revenue beat, raised guidance By Investing.com - Investing.com South Africa
Exact Sciences stock surges 8% on Q1 revenue beat, raised guidance - Investing.com Australia
EXACT SCIENCES CORP SEC 10-Q Report - TradingView
Exact Sciences (EXAS) Q1 Revenue Beats Expectations, Raises Full-Year Outlook | EXAS Stock News - GuruFocus
Earnings Flash (EXAS) Exact Sciences Posts Q1 Revenue $706.8M, vs. FactSet Est of $688.6M - marketscreener.com
Exact Sciences Crushes Q1 Earnings: Revenue Surges 11%, Launches Revolutionary Cancer Detection Tests - Stock Titan
Global Molecular Diagnostics Market to Expand at a CAGR of ~9% by 2032 Due to the Rising Demand for Precision Medicine | DelveInsight - GlobeNewswire Inc.
Exact Sciences reports Q1 results that top analysts’ expectations - Wisconsin State Journal
Exact Sciences (EXAS) Reports Q1: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Exact Sciences appoints new board member - Investing.com
Form DEF 14A EXACT SCIENCES CORP For: Jun 12 - StreetInsider
Exact Sciences to Highlight Cologuard® Test Adherence and Predic - GuruFocus
Exact Sciences to Highlight Cologuard Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025 - Business Wire
This Exact Sciences Insider Increased Their Holding In The Last Year - Yahoo Finance
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):